Key Highlights
- Loss per share of USD 0.25, where a USD 0.28 loss was expected.
- Net loss of USD 51.22 million, against USD 54.92 million a year earlier.
- Research and development expenses fell USD 8.3 million, or 17%.
- Cash and cash equivalents were USD 102.39 million on September 30.
Annexon (NASDAQ:ANNX) lost USD 0.25 per share in the third quarter of 2026. The market had expected a loss of USD 0.28, and the third quarter of 2025 brought a loss of USD 0.37. The net loss was USD 51.22 million, against USD 54.92 million in the prior-year quarter.
The loss from operations was USD 52.24 million, against USD 57.02 million. Total operating expenses were the same USD 52.24 million, against USD 57.02 million, a drop of USD 4.78 million, or 8%.
Spending Moves in Opposite Directions
Research and development expenses were USD 8.3 million, or 17%, lower than in the same period of 2025. General and administrative expenses rose USD 3.6 million, or 49%, chiefly because consulting and professional services costs for corporate affairs grew by USD 2.0 million in support of the late-stage tanruprubart and vonaprument programs.
Interest expense was USD 0.83 million, with none a year earlier. Net interest and other income was USD 0.2 million, or 12%, lower.
Nine Months and the Cash Position
For the nine months ended September 30, 2026, the net loss was USD 150.71 million, against USD 158.43 million, and the loss per share was USD 0.75, against USD 1.08. Total operating expenses were USD 155.52 million, against USD 166.15 million, and they matched the loss from operations in both periods.
Cash, cash equivalents and restricted cash were USD 103.42 million at September 30, 2026, against USD 163.08 million at December 31, 2025, with USD 1.03 million of restricted cash in both periods. Cash and cash equivalents were USD 102.39 million, against USD 162.05 million at the prior Balance Sheet date, while short-term investments were USD 110.99 million, against USD 76.29 million.
Clinical Backdrop
The filing says the FDA has approved no therapy for Guillain-Barre syndrome and that the current standard of care lacks substantial evidence of effectiveness. In the placebo-controlled Phase 3 trial of tanruprubart, about 90% of treated patients improved by week 1, and more than twice as many treated patients reached a normal state of health at week 26.
The FORWARD study, the filing adds, showed functional outcomes, complete target engagement and a generally well-tolerated safety profile, in line with Phase 3 and real-world evidence studies. It also notes that no approved therapy exists for geographic atrophy aimed at preserving vision.
The Quarter in Brief
Annexon reported a loss of USD 0.25 per share and a net loss of USD 51.22 million. Total operating expenses were USD 52.24 million, cash and cash equivalents were USD 102.39 million, and short-term investments were USD 110.99 million.





_11_19_2026_19_57_40_035532.jpg)
Please wait processing your request...